Toyama University Hospital Comprehensive Cancer Center　

The Blood Oncology Center is led by five specialists from the Japanese Society of Hematology, all of them advising doctors, and provides a high level of medical care. We work at the cutting edge of new drug therapies, offering the newest in ever-evolving hematological treatment.
We provide comprehensive coverage of all blood diseases, including anemia, leukemia, malignant lymphoma, multiple myeloma, and thrombocytopenia. We also focus on medical transplantation, as a Japan Marrow Donor Program-certified transplant hospital.
We value cooperation with local medical care providers, to enable more patients to receive better medical care.

Bone-Friendly Treatment of Malignant Lymphoma

With the arrival of the new antibody drug rituximab, therapeutic outcomes for malignant lymphoma have seen a remarkable improvement. Though it promises long-term prognoses, many patients suffer from osteoporosis as a side effect of the adrenocorticosteroids used in treatment: these can cause complications such as compression fractures, leading to reduced quality of life. As part of our efforts to take life after lymphoma treatment into consideration as well, we administer drugs such as denosumab and zoledronic acid to help prevent osteoporosis in patients who would be at high risk of developing this side effect.

Advanced Genetic Testing

Hematological treatments are ever-evolving, and more and more diseases require genetic testing for an accurate diagnosis. At the same time, however, a limited number of genetic tests are covered by national health insurance. This means that the testing system has been unable to keep up with the increasing number of genetic tests that are needed.
We also offer individualized genetic tests that are not performed on a commercial basis, as necessary.